Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
 - EconoTimes)
NEW YORK, March 10, 2016 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Horizon Pharma plc (“Horizon” or the “Company”) (Nasdaq:HZNP) in the United States District Court for the Southern District of New York on behalf of a class consisting of all persons or entities who purchased Horizon securities between March 13, 2014 and February 26, 2016, inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that Defendants made materially false and misleading statements to investors and/or failed to disclose that: (1) Horizon Pharma’s Prescriptions Made Easy (“PME”) program was set up to artificially inflate the prices of minor differentiation standard retail drugs; (2) sales revenues from drugs sold through Horizon Pharma’s PME program could not be sustained at these inflated price levels; (3) Horizon Pharma’s use of its PME program exposed Horizon Pharma to increased regulatory risks, and (4) as a result, Horizon Pharma’s financial statements were materially false and misleading at all relevant times. When the true details entered the market, the Complaint alleges that the price of the stock dropped sharply and investors suffered damages.
If you wish to serve as lead plaintiff, you must move the Court no later than May 9, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.
